Bioceres Crop Solutions Corp.(BIOX)Earnings, Financials & Key Ratios
BIOX•NASDAQ
Price updated Jun 19, 2026
AboutBioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through three segments: Seed and Integrated Products, Crop Protection, and Crop Nutrition. The Seed and Integrated Products segment develops and commercializes seed technology, biotechnological events, germplasm, and seed treatments. The Crop Protection segment develops, produces, and markets Rizoderma, adjuvants, therapies, herbicides, insecticides, fungicides, and baits. The Crop Nutrition segment develops, produces, commercializes, and sells inoculants, bio-inductors, and biological and microgranulated fertilizers. The company also offers HB4, a drought tolerant seed technology program. It operates in Argentina, Uruguay, France, South Africa, and internationally. The company was founded in 2001 and is headquartered in Rosario, Argentina. Bioceres Crop Solutions Corp. is a subsidiary of Bioceres LLC.Show more
- Revenue$333M-28.3%
- EBITDA$14M-79.3%
- Net Income-$52M-1697.3%
- EPS (Diluted)-0.82-1704.7%
- Gross Margin39.06%
- EBITDA Margin4.11%-71.1%
- Operating Margin-1.11%-111.5%
- Net Margin-15.54%-2327.5%
- ROE-16.02%-1784.4%
BIOX Key Insights
Bioceres Crop Solutions Corp. (BIOX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 14.1%
- ✓Trading at only 0.1x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Weak momentum: RS Rating 5 (bottom 5%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BIOX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BIOX Price & Volume
Bioceres Crop Solutions Corp. (BIOX) stock price & volume — 10-year historical chart
Loading chart...
BIOX Growth Metrics
Bioceres Crop Solutions Corp. (BIOX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years14.1%
3 Years0.49%
TTM-28.69%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-15822.86%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-12974.39%
Return on Capital
10 Years14.04%
5 Years11.18%
3 Years7.04%
Last Year-0.78%
BIOX Recent Earnings
Bioceres Crop Solutions Corp. (BIOX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (17%)●Beat Revenue 2/12 qtrs (17%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.16-220.0%
$0.05
Rev
$39M-27.7%
$55M
Q2 2026
Mar 13, 2026Metric
Actual
Est
EPS
$0.08-214.3%
$0.07
Rev
$74M-23.3%
$96M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.12-200.0%
$0.04
Rev
$77M-14.2%
$90M
Q2 2025
May 21, 2025Metric
Actual
Est
EPS
$0.02+80.0%
$0.10
Rev
$60M-46.7%
$112M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.16vs $0.05-220.0% | $39Mvs $55M-27.7% |
| Q2 2026 | Mar 13, 2026 | $0.08vs $0.07-214.3% | $74Mvs $96M-23.3% |
| Q4 2025 | Nov 12, 2025 | $0.12vs $0.04-200.0% | $77Mvs $90M-14.2% |
| Q2 2025 | May 21, 2025 | $0.02vs $0.10+80.0% | $60Mvs $112M-46.7% |
Based on last 12 quarters of dataView full earnings history →
BIOX Peer Comparison
Bioceres Crop Solutions Corp. (BIOX) competitors in Seeds and crop genetics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PGEN | 1.45B | 4.82 | -3.42 | 146.73% | -6.47% | -17.69% | 0.24 | |
 FMC | 1.44B | 11.55 | -0.65 | -18.34% | -72.93% | -82.27% | 2.00 | |
 CTVA | 52.74B | 78.56 | 49.10 | 2.92% | 6.5% | 4.62% | 0.11 | |
 AVD | 75.81M | 2.65 | -1.51 | -5.88% | -8.71% | -21.86% | 0.99 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 RKDA | 1.2M | 0.78 | -0.45 | -3.71% | -195.94% | -219.35% | ||
 DE | 159.06B | 589.24 | 31.85 | -11.59% | 10.21% | 18.21% | 2.46 | |
 CF | 15.81B | 102.93 | 11.47 | 19.34% | 23.73% | 22.29% | 0.51 |
Compare BIOX vs Peers
Bioceres Crop Solutions Corp. (BIOX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BIOX Income Statement
Bioceres Crop Solutions Corp. (BIOX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 93.71M | 133.49M | 160.31M | 172.35M | 206.7M | 328.46M | 419.45M | 464.83M | 333.3M | 285.11M |
Revenue Growth % | - | 42.46% | 20.09% | 7.51% | 19.93% | 58.91% | 27.7% | 10.82% | -28.3% | -28.69% |
Cost of Goods Sold | 59.86M | 77.09M | 86.68M | 92.86M | 115.82M | 202.02M | 239.2M | 283.24M | 203.1M | 175.48M |
COGS % of Revenue | 63.88% | 57.75% | 54.07% | 53.88% | 56.03% | 61.51% | 57.03% | 60.93% | 60.94% | - |
Gross Profit | 33.85M▲ 0% | 56.4M▲ 66.6% | 73.62M▲ 30.5% | 79.49M▲ 8.0% | 90.88M▲ 14.3% | 126.44M▲ 39.1% | 180.25M▲ 42.6% | 181.59M▲ 0.7% | 130.2M▼ 28.3% | 109.63M▲ 0% |
Gross Margin % | 36.12% | 42.25% | 45.93% | 46.12% | 43.97% | 38.49% | 42.97% | 39.07% | 39.06% | 38.45% |
Gross Profit Growth % | - | 66.62% | 30.55% | 7.97% | 14.33% | 39.12% | 42.56% | 0.74% | -28.3% | - |
Operating Expenses | 41.32M | 38.55M | 41.83M | 41.32M | 49.97M | 84.91M | 111.76M | 136.77M | 133.9M | 108.01M |
OpEx % of Revenue | 44.09% | 28.88% | 26.1% | 23.98% | 24.18% | 25.85% | 26.64% | 29.42% | 40.17% | - |
Selling, General & Admin | 27.39M | 35.26M | 30.84M | 29.48M | 44.39M | 57.36M | 85.54M | 94.27M | 88.35M | 72.84M |
SG&A % of Revenue | 29.23% | 26.42% | 19.24% | 17.1% | 21.47% | 17.46% | 20.39% | 20.28% | 26.51% | - |
Research & Development | 3.98M | 3.95M | 3.69M | 4.2M | 5.62M | 6.95M | 15.35M | 17.18M | 0 | 11.72M |
R&D % of Revenue | 4.25% | 2.96% | 2.3% | 2.43% | 2.72% | 2.12% | 3.66% | 3.7% | - | - |
Other Operating Expenses | 0 | 0 | 0 | 7.65M | -34.25K | 20.6M | 10.87M | 25.32M | 45.55M | 2M |
Operating Income | -706.92K▲ 0% | 15.71M▲ 2322.4% | 32.09M▲ 104.2% | 39.15M▲ 22.0% | 38.38M▼ 1.9% | 39.87M▲ 3.9% | 54.18M▲ 35.9% | 44.82M▼ 17.3% | -3.7M▼ 108.3% | 1.62M▲ 0% |
Operating Margin % | -0.75% | 11.77% | 20.01% | 22.71% | 18.57% | 12.14% | 12.92% | 9.64% | -1.11% | 0.57% |
Operating Income Growth % | - | 2322.44% | 104.22% | 22% | -1.95% | 3.87% | 35.9% | -17.28% | -108.26% | - |
EBITDA | 3.9M | 20.08M | 36.91M | 43.88M | 44.65M | 49.06M | 73.57M | 66.12M | 13.69M | 19.03M |
EBITDA Margin % | 4.16% | 15.04% | 23.03% | 25.46% | 21.6% | 14.94% | 17.54% | 14.22% | 4.11% | 6.68% |
EBITDA Growth % | - | 415.03% | 83.8% | 18.87% | 1.75% | 9.88% | 49.98% | -10.14% | -79.29% | -68.17% |
D&A (Non-Cash Add-back) | 4.61M | 4.37M | 4.83M | 4.73M | 6.26M | 9.19M | 19.39M | 21.3M | 17.39M | 17.41M |
EBIT | -706.92K | -12.77K | 12.46M | 25.84M | 37.44M | 38.73M | 52.99M | 34.16M | -3.8M | -5.6M |
Net Interest Income | 0 | 0 | -44.34M | -11.66M | -21.24M | -17.93M | -23.79M | -26.87M | -50.1M | -47.88M |
Interest Income | 14.92M | 0 | 1.49M | 7.73M | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 21.84M | 19.4M | 21.24M | 17.93M | 23.79M | 26.87M | 50.1M | 47.88M |
Other Income/Expense | -21.68M | -40.95M | -41.46M | 0 | -27.85M | -25.81M | -35.08M | -34.78M | -50.2M | -55.15M |
Pretax Income | -22.39M▲ 0% | -25.24M▼ 12.7% | -9.37M▲ 62.9% | 6.44M▲ 168.7% | 10.53M▲ 63.4% | 14.06M▲ 33.6% | 19.11M▲ 35.9% | 10.04M▼ 47.5% | -53.9M▼ 637.1% | -53.53M▲ 0% |
Pretax Margin % | -23.9% | -18.91% | -5.85% | 3.74% | 5.09% | 4.28% | 4.55% | 2.16% | -16.17% | -18.77% |
Income Tax | -5.63M | -10.93M | 6.99M | 2.21M | 14.35M | 17.97M | -1.07M | 3.78M | 1.3M | 7.99M |
Effective Tax Rate % | 25.16% | 43.3% | -74.54% | 34.25% | 136.28% | 127.79% | -5.59% | 37.66% | -2.41% | -14.92% |
Net Income | -11.82M▲ 0% | -11.04M▲ 6.6% | -18.37M▼ 66.4% | 3.36M▲ 118.3% | -6.87M▼ 304.5% | -7.2M▼ 4.8% | 18.78M▲ 360.8% | 3.24M▼ 82.7% | -51.8M▼ 1697.3% | -235.97M▲ 0% |
Net Margin % | -12.61% | -8.27% | -11.46% | 1.95% | -3.32% | -2.19% | 4.48% | 0.7% | -15.54% | -82.77% |
Net Income Growth % | - | 6.59% | -66.39% | 118.29% | -304.52% | -4.8% | 360.85% | -82.73% | -1697.29% | -15822.86% |
Net Income (Continuing) | -16.76M | -14.31M | -16.36M | 1.76M | -3.82M | -3.91M | 20.17M | 6.26M | -55.2M | -61.51M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1000K |
Minority Interest | 41.4M | 19.42M | 14.79M | 14.57M | 22.55M | 30.68M | 31.65M | 36.08M | 32.41M | 32.85M |
EPS (Diluted) | -0.42▲ 0% | -0.39▲ 7.1% | -0.60▼ 53.8% | 0.09▲ 115.4% | -0.18▼ 295.2% | -0.17▲ 5.6% | 0.30▲ 276.5% | 0.05▼ 83.0% | -0.82▼ 1704.7% | -3.72▲ 0% |
EPS Growth % | - | 7.14% | -53.85% | 115.37% | -295.23% | 5.56% | 276.47% | -82.97% | -1704.7% | -12974.39% |
EPS (Basic) | -0.42 | -0.39 | -0.60 | 0.09 | -0.18 | -0.17 | 0.30 | 0.05 | -0.82 | - |
Diluted Shares Outstanding | 28.1M | 28.1M | 30.48M | 36.42M | 39.22M | 42.3M | 63.19M | 63.48M | 63.2M | 63.48M |
Basic Shares Outstanding | 28.1M | 28.1M | 30.48M | 36.12M | 39.22M | 42.3M | 62.15M | 62.84M | 63.2M | 63.48M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
BIOX Balance Sheet
Bioceres Crop Solutions Corp. (BIOX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 87.77M | 85.34M | 98.21M | 164.69M | 211.49M | 297.71M | 397.11M | 408.67M | 308.31M | 294.28M |
Cash & Short-Term Investments | 1.68M | 2.23M | 3.81M | 55.96M | 46.78M | 38.61M | 60.05M | 56.17M | 34.74M | 12.58M |
Cash Only | 1.68M | 2.22M | 3.45M | 27.16M | 36.05M | 33.48M | 48.13M | 44.47M | 32.7M | 11.06M |
Short-Term Investments | 4.28K | 12.53K | 356.23K | 28.8M | 10.74M | 5.14M | 11.92M | 11.7M | 2.04M | 1.52M |
Accounts Receivable | 41.68M | 52.89M | 59.24M | 77.84M | 99.15M | 128.08M | 185.32M | 216.03M | 177.75M | 165.84M |
Days Sales Outstanding | 162.33 | 144.61 | 134.87 | 164.85 | 175.08 | 142.33 | 161.26 | 169.64 | 194.66 | 228.28 |
Inventory | 31.34M | 19.37M | 27.59M | 30.77M | 63.35M | 126.1M | 140.57M | 126.22M | 89.99M | 67.15M |
Days Inventory Outstanding | 191.09 | 91.69 | 116.18 | 120.93 | 199.66 | 227.84 | 214.51 | 162.66 | 161.72 | 177 |
Other Current Assets | 12.8M | 10.86M | 7.36M | 128.65K | 425.98K | 265.12K | 212.7K | 0 | 0 | 42.36M |
Total Non-Current Assets | 152.1M | 111.3M | 144.26M | 132.87M | 183.1M | 220.52M | 420.94M | 443.88M | 455.33M | 266.08M |
Property, Plant & Equipment | 46.22M | 40.18M | 43.83M | 42.63M | 49.28M | 62.05M | 81.79M | 86.18M | 90.95M | 72.06M |
Fixed Asset Turnover | 2.03x | 3.32x | 3.66x | 4.04x | 4.19x | 5.29x | 5.13x | 5.39x | 3.66x | 3.31x |
Goodwill | 25.08M | 14.44M | 29.8M | 25.53M | 28.75M | 36.07M | 112.16M | 112.16M | 112.16M | 36.07M |
Intangible Assets | 42.06M | 26.66M | 39.62M | 35.33M | 67.34M | 76.7M | 173.78M | 176.89M | 181.17M | 87.29M |
Long-Term Investments | 32.88M | 19.32M | 25.7M | 26.35M | 31.75M | 39.17M | 39.74M | 40.42M | 39.37M | 183.63M |
Other Non-Current Assets | 5.87M | 5.11M | 1.56M | 334.73K | 2.69M | 2.5M | 6.15M | 18.53M | 26.76M | 25.66M |
Total Assets | 239.87M▲ 0% | 196.64M▼ 18.0% | 242.47M▲ 23.3% | 297.56M▲ 22.7% | 394.59M▲ 32.6% | 518.22M▲ 31.3% | 818.06M▲ 57.9% | 852.55M▲ 4.2% | 763.65M▼ 10.4% | 560.36M▲ 0% |
Asset Turnover | 0.39x | 0.68x | 0.66x | 0.58x | 0.52x | 0.63x | 0.51x | 0.55x | 0.44x | 0.40x |
Asset Growth % | - | -18.02% | 23.31% | 22.72% | 32.61% | 31.33% | 57.86% | 4.22% | -10.43% | -58.83% |
Total Current Liabilities | 69.39M | 118.68M | 116.46M | 130.61M | 168.04M | 222.67M | 298.71M | 329.31M | 337.99M | 328.64M |
Accounts Payable | 22.28M | 26.08M | 38.66M | 54.79M | 69.31M | 124.41M | 146.29M | 161.93M | 91.58M | 82.54M |
Days Payables Outstanding | 135.86 | 123.48 | 162.78 | 215.37 | 218.42 | 224.77 | 223.23 | 208.67 | 164.58 | 201.52 |
Short-Term Debt | 33.57M | 65.03M | 66.09M | 64.39M | 76.79M | 71.3M | 107.64M | 136.75M | 222M | 194.42M |
Deferred Revenue (Current) | 0 | 1.02M | 1.08M | 2.87M | 6.28M | 5.9M | 24.88M | 3.92M | 4.28M | 12.97M |
Other Current Liabilities | 7.65M | 22.84M | 4.49M | 2.5M | 2.79M | 10.67M | 5.93M | 11.96M | 7.94M | 33.12M |
Current Ratio | 1.26x | 0.72x | 0.84x | 1.26x | 1.26x | 1.34x | 1.33x | 1.24x | 0.91x | 0.90x |
Quick Ratio | 0.81x | 0.56x | 0.61x | 1.03x | 0.88x | 0.77x | 0.86x | 0.86x | 0.65x | 0.69x |
Cash Conversion Cycle | 217.56 | 112.81 | 88.27 | 70.41 | 156.33 | 145.39 | 152.54 | 123.63 | 191.81 | 203.76 |
Total Non-Current Liabilities | 90.74M | 44.82M | 63.91M | 106.9M | 136.26M | 137.26M | 188.85M | 171.86M | 130.44M | 125.11M |
Long-Term Debt | 40.27M | 25.25M | 36.62M | 84.96M | 96.65M | 86.74M | 135.88M | 122.91M | 38.2M | 34.16M |
Capital Lease Obligations | 678.99K | 454.26K | 462.87K | 444.71K | 390.41K | 10.34M | 10.03M | 8.16M | 9.53M | 41.31M |
Deferred Tax Liabilities | 0 | 13.59M | 21.1M | 16.86M | 25.7M | 29.01M | 35.79M | 35M | 30.12M | 116.28M |
Other Non-Current Liabilities | 49.79M | 19.12M | 5.72M | 4.64M | 13.52M | 11.18M | 5.09M | 3.86M | 51.15M | 54M |
Total Liabilities | 160.13M | 163.51M | 180.37M | 237.51M | 304.3M | 359.92M | 487.56M | 501.17M | 468.43M | 453.75M |
Total Debt | 74.99M | 91.02M | 103.56M | 149.79M | 174.58M | 169.79M | 257.41M | 270.95M | 276.61M | 239.46M |
Net Debt | 73.31M | 88.8M | 100.11M | 122.63M | 138.53M | 136.31M | 209.28M | 226.47M | 243.91M | 228.39M |
Debt / Equity | 0.94x | 2.75x | 1.67x | 2.49x | 1.93x | 1.07x | 0.78x | 0.77x | 0.94x | 2.25x |
Debt / EBITDA | 19.23x | 4.53x | 2.81x | 3.41x | 3.91x | 3.46x | 3.50x | 4.10x | 20.20x | 12.58x |
Net Debt / EBITDA | 18.80x | 4.42x | 2.71x | 2.79x | 3.10x | 2.78x | 2.84x | 3.43x | 17.81x | 12.00x |
Interest Coverage | - | - | 0.57x | 1.33x | 1.76x | 2.16x | 2.23x | 1.27x | -0.08x | -0.12x |
Total Equity | 79.74M▲ 0% | 33.13M▼ 58.4% | 62.09M▲ 87.4% | 60.05M▼ 3.3% | 90.29M▲ 50.4% | 158.3M▲ 75.3% | 330.5M▲ 108.8% | 351.38M▲ 6.3% | 295.22M▼ 16.0% | 106.62M▲ 0% |
Equity Growth % | - | -58.45% | 87.41% | -3.3% | 50.37% | 75.32% | 108.78% | 6.32% | -15.98% | -105.08% |
Book Value per Share | 2.84 | 1.18 | 2.04 | 1.65 | 2.30 | 3.74 | 5.23 | 5.53 | 4.67 | 1.68 |
Total Shareholders' Equity | 38.34M | 13.71M | 47.3M | 45.48M | 67.74M | 127.61M | 298.85M | 315.3M | 262.81M | 73.77M |
Common Stock | 2.81K | 2.81K | 3.61K | 3.61K | 4.16K | 4.64K | 6.49K | 6.5K | 6.5K | 6.5K |
Retained Earnings | -15.11M | -26.15M | -21.97M | -18.61M | -25.48M | -32.68M | -13.9M | -9.63M | -65.04M | -255.41M |
Treasury Stock | 0 | 0 | 0 | -30.91K | -4.45M | -3.53M | -30.55M | -31.29M | -32.21M | -25.17M |
Accumulated OCI | -5.31M | -28.27M | -27.22M | -32.37M | -27.37M | 1.98M | 1.12M | 633.49K | 91.81K | 61.65K |
Minority Interest | 41.4M | 19.42M | 14.79M | 14.57M | 22.55M | 30.68M | 31.65M | 36.08M | 32.41M | 32.85M |
BIOX Cash Flow Statement
Bioceres Crop Solutions Corp. (BIOX) cash flow — operating, investing & free cash flow history
| Metric | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 19.1M | 18.39M | 29.69M | 9.32M | -6.21M | -17.52M | 2.59M | 41.72M | 49.91M | 74.89M |
Operating CF Margin % | 20.38% | 13.77% | 18.52% | 5.41% | -3% | -5.33% | 0.62% | 8.97% | 14.97% | - |
Operating CF Growth % | - | -3.74% | 61.5% | -68.62% | -166.6% | -182.24% | 114.78% | 1511.45% | 19.63% | 353.36% |
Net Income | -11.82M | -14.31M | -16.36M | 4.24M | -3.82M | -3.91M | 20.17M | 6.26M | -58.85M | -235.97M |
Depreciation & Amortization | 4.61M | 4.37M | 4.83M | 4.73M | 6.26M | 9.19M | 19.39M | 21.3M | 22.18M | 20.3M |
Stock-Based Compensation | 51.42K | 30K | -102.83K | 3.43M | 1.66M | 1.43M | 3.42M | 14.13M | 4.39M | 2.05M |
Deferred Taxes | 0 | -10.93M | 6.99M | 2.21M | 14.35M | 17.97M | -1.07M | 3.78M | 1.27M | 3.41M |
Other Non-Cash Items | -15.24M | 47.32M | 45.79M | 33.51M | 29.23M | 18.65M | 45.78M | 37.76M | 61.61M | 59.56M |
Working Capital Changes | 41.51M | -8.09M | -11.44M | -38.8M | -53.88M | -60.85M | -85.11M | -41.51M | 19.3M | 55.32M |
Change in Receivables | 33.49M | 17.32M | 41.49M | -21.74M | 1.99M | -24.97M | -56.87M | -51.65M | 24.58M | 37.61M |
Change in Inventory | -2.25M | 10.36M | -8.64M | -5.31M | -34.5M | -55.31M | -11.07M | 14.18M | 34.91M | 28.21M |
Change in Payables | 0 | -35.29M | -33.7M | 8.27M | -5.83M | 53.48M | -4.5M | 14.23M | -32.04M | -1.29M |
Cash from Investing | -20.16M | -8.22M | -3.26M | -7.8M | -8.31M | 2.9M | -25.73M | -28.73M | -6.13M | -5.08M |
Capital Expenditures | -1.39M | -5.71M | -3.45M | -4.5M | -13.92M | -9M | -22.56M | -9.79M | -5.64M | -3.29M |
CapEx % of Revenue | 1.48% | 4.28% | 2.15% | 2.61% | 6.74% | 2.74% | 5.38% | 2.11% | 1.69% | 1.16% |
Acquisitions | 0 | 0 | -129.34K | 51.15K | 253.92K | -3.49M | 4.37M | 37.51K | 390.38K | 26.5K |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -18.77M | -2.51M | 317.95K | 0 | 309.81K | 5.12M | 137.36K | -12.66M | -8.97M | -5.5M |
Cash from Financing | 2.33M | -10.46M | -26.95M | 33.53M | 7.36M | 14.82M | 32.95M | -10.06M | -50.71M | -78.11M |
Debt Issued (Net) | 0 | -9.88M | -22.39M | 31.26M | 29.67M | 28.74M | 59.22M | 18.32M | -27.57M | -67.78M |
Equity Issued (Net) | 0 | 0 | 0 | -30.91K | -3.5M | 0 | -3M | -734K | -926.9K | 488.29K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | -30.91K | -3.5M | 0 | -3M | -734K | -926.9K | 0 |
Other Financing | 2.33M | -578.29K | -4.55M | 2.3M | -18.81M | -13.91M | -23.27M | -27.65M | -22.21M | -10.82M |
Net Change in Cash | 1.39M▲ 0% | 535.63K▼ 61.6% | 1.24M▲ 130.7% | 39.07M▲ 3061.8% | -6.48M▼ 116.6% | -2.57M▲ 60.3% | 14.65M▲ 670.0% | -3.66M▼ 124.9% | -11.78M▼ 222.2% | -18.11M▲ 0% |
Free Cash Flow | 17.71M▲ 0% | 12.68M▼ 28.4% | 26.25M▲ 107.0% | 4.82M▼ 81.6% | -20.13M▼ 517.9% | -26.51M▼ 31.7% | -19.97M▲ 24.7% | 18.93M▲ 194.8% | 35.3M▲ 86.4% | 68.86M▲ 0% |
FCF Margin % | 18.9% | 9.5% | 16.37% | 2.79% | -9.74% | -8.07% | -4.76% | 4.07% | 10.59% | 24.15% |
FCF Growth % | - | -28.41% | 107% | -81.65% | -517.94% | -31.71% | 24.66% | 194.79% | 86.43% | 54585.13% |
FCF per Share | 0.63 | 0.45 | 0.86 | 0.13 | -0.51 | -0.63 | -0.32 | 0.30 | 0.56 | 1.08 |
FCF Conversion (FCF/Net Income) | -1.62x | -1.67x | -1.62x | 2.77x | 0.90x | 2.43x | 0.14x | 12.86x | -0.96x | -0.29x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BIOX Key Ratios
Bioceres Crop Solutions Corp. (BIOX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -19.56% | -38.58% | 5.5% | -9.14% | -5.79% | 7.68% | 0.95% | -16.02% | -92.01% |
Return on Invested Capital (ROIC) | 8.57% | 16.94% | 17.03% | 13.99% | 11.43% | 9.74% | 6.02% | -0.5% | 0.24% |
Gross Margin | 42.25% | 45.93% | 46.12% | 43.97% | 38.49% | 42.97% | 39.07% | 39.06% | 38.45% |
Net Margin | -8.27% | -11.46% | 1.95% | -3.32% | -2.19% | 4.48% | 0.7% | -15.54% | -82.77% |
Debt / Equity | 2.75x | 1.67x | 2.49x | 1.93x | 1.07x | 0.78x | 0.77x | 0.94x | 2.25x |
Interest Coverage | - | 0.57x | 1.33x | 1.76x | 2.16x | 2.23x | 1.27x | -0.08x | -0.12x |
FCF Conversion | -1.67x | -1.62x | 2.77x | 0.90x | 2.43x | 0.14x | 12.86x | -0.96x | -0.29x |
Revenue Growth | 42.46% | 20.09% | 7.51% | 19.93% | 58.91% | 27.7% | 10.82% | -28.3% | -28.69% |
Related:BIOX Dividend History·BIOX Revenue History·BIOX Price History·BIOX P/E History·BIOX Financial Ratios·BIOX Institutional Holders
BIOX Frequently Asked Questions
Bioceres Crop Solutions Corp. (BIOX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Bioceres Crop Solutions Corp. (BIOX) reported $285.1M in revenue for fiscal year 2025. This represents a 204% increase from $93.7M in 2017.
Bioceres Crop Solutions Corp. (BIOX) saw revenue decline by 28.3% over the past year.
Bioceres Crop Solutions Corp. (BIOX) reported a net loss of $236.0M for fiscal year 2025.
Dividend & Returns
Bioceres Crop Solutions Corp. (BIOX) has a return on equity (ROE) of -16.0%. Negative ROE indicates the company is unprofitable.
Bioceres Crop Solutions Corp. (BIOX) generated $68.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.